|
|
Build Your Online Product Catalogs?
| Product Name: |
Nootropic Powder Nsi-189/nootropic@ycgmp.com
|
| Supply Ability: |
500kg/month |
| Related proudcts |
nsi-189, |
| Specifications |
99% |
| Price Term: |
CNF |
| Port of loading: |
HK/Shanghai/Shenzhen |
| Minimum Order |
5g |
| Unit Price: |
$1 |
|
NSI-189
Product Name: NSI-189
CAS: 1270138-40-3
MF: C22H30N4O
MW: 366.4998
Purity: 99%
MP: 83°C-86°C
Grade: Pharmaceutical Grade
Appearance: White Powder
Description
NSI-189 is neurogenic and nootropic research agent that was developed from nicotinamide and pyrazine.
Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, it has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression.
It is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer's disease and age-related cognitive problems.
Development of NSI-189
NSI-189 is an experimental drug currently being developed and studied by Neuralstem Inc.. The researchers at Neuralstem recognized that a drug targeting the hippocampus could possibly alleviate the effects of sleep deprivation and exhaustion, and set out to find a drug that could induce neurogenesis. This preliminary research would eventually result in the drug NSI-189.
Clinical research on NSI-189 has been in the works since 2011, and a phase 1b trial was completed in July of 2014. Clinical phase 1 trials typically focus on finding the correct dosage range of the drug, which has been placed around 40 to 80 mg per day in the treatment of Major Depressive Disorder (MDD) and cognitive decline.
The phase 1b trial of NSI-189 was "a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD." Now that the trial has been completed, the results have been released, and they appear quite promising.
The study, which was conducted on 24 patients over the course of 28 days, found that NSI-189 administration reduced the symptoms of depression and cognitive decline significan |
| Company: |
Hangzhou Fuluo Biological Technology Co.,Ltd
|
| Contact: |
Ms. Cindy Lee |
| Address: |
4#Xinfeng Road,Hongjie Street,Jianggan District |
| Postcode: |
310017 |
| Tel: |
86-0571-87963072 |
| Fax: |
86-0571-87963072 |
| E-mail: |
|
|
|
|
Home
